HAMILTON, ON – October 16, 2026 – CPDC (Centre for Probe Development and Commercialization) is pleased to announce the appointment of Dr. Lana Janes as Chief Scientific Officer of the company, effective October 16, 2026. Dr. Janes has served on CPDC’s Board of Directors since 2021, providing strategic leadership during a period of significant changes and growth for the organization. Transitioning from the Board to the leadership team, she will help shape CPDC’s scientific direction and support the continued expansion of its radiopharmaceutical research, development, and commercialization activities.
Dr. Janes brings extensive experience in building and leading Canadian biopharmaceutical companies, most recently serving as a Co-Founder and Chief Operating Officer of Abdera Therapeutics. Prior to her work at Abdera, Dr. Janes spent 12 years at QLT Inc., serving as Chief Patent Officer where she developed and strategically managed all aspects of intellectual property for the company’s preclinical, clinical and commercial stage therapeutic and medical device assets, and later as Senior Vice President of Technology Development, with full responsibility for leading the R&D organization and overseeing all aspects of the Company’s pipeline of clinical stage programs. Throughout her career, she has successfully translated scientific innovation into impactful development programs, strategic partnerships, and organizational growth, including within the rapidly evolving radiopharmaceutical sector.
She holds a Bachelor’s Degree in Chemistry from Harvard University, and a Ph.D. in organic chemistry from McGill University, where she also conducted her Post-doctoral research.
“As CPDC continues to expand its impact across the radiopharmaceutical ecosystem in Canada and around the world, having Lana’s scientific, operational, and strategic expertise will be invaluable,” said Owen Roberts, Chief Executive Officer of CPDC. “Having worked closely with Lana through her service on our Board, I have seen firsthand her commitment to scientific excellence, entrepreneurial mindset, and her ability to identify and advance high-potential opportunities. We are delighted to welcome Lana to the CPDC team and look forward to the important contributions she will make in this new role.”
As Chief Scientific Officer, Dr. Janes will provide scientific leadership across CPDC’s portfolio of radiopharmaceutical development initiatives. Working closely with the leadership team and external partners, she will help accelerate the advancement of innovative radiopharmaceuticals for the benefit of patients and the broader healthcare community.
“I am honoured to join CPDC at such an exciting time in its evolution,” said Dr. Lana Janes. “CPDC has established itself as a unique organization within the global radiopharmaceutical community by combining scientific expertise, commercialization capabilities, strategic investments, and ecosystem development. I look forward to working with the talented team at CPDC and our partners to advance important innovations and strengthen Canada’s leadership in radiopharmaceuticals both at home and globally.”
About CPDC
CPDC is a not-for-profit corporation founded in 2008, with the mission to improve the quality of Canadian patients’ lives through the commercialization of advanced research and the clinical development of nuclear medicine. In the past 18 years, CPDC has created four Canadian commercial entities that have advanced the availability of radiopharmaceuticals to the Canadian medical community. CPDC’s business model will continue to identify and advance critical radiopharmaceuticals to meet the needs of Canadian patients and physicians through commercialization and collaborations with its partners from industry, academia, and government.
For more information on CPDC visit www.cpdc.ca and follow on LinkedIn.
Contact:
Owen Roberts
CEO, CPDC
owen@cpdc.ca